ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-c-Met Antibody-drug Conjugate YL211

Also written as “YL211”, “YL211+Pembrolizumab” and “YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)”.

In hoffmann la roche’s pipeline, cMET ADC. Its studies are led by MediLink Therapeutics (Suzhou).

Furthest: phase 1, since Mar 26, 20241 company-led study, 1 open or runningNext primary completion: Jun 30, 2031 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MediLink Therapeutics (Suzhou)11 open or runningphase 1since Mar 26, 2024Mar 26, 2024Jun 30, 2031phase 1 · NCT06384352
  • Named in hoffmann la roche’s own pipeline as RG6648 cMET ADC (MediLink), phase 1, as of Oct 22, 2026 (source).

Also a collaborator on its studies: Hoffmann-La Roche.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 26, 2024First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06384352 · 500 planned · United States, Australia, Canada and more

Ahead

  1. Jun 30, 2031Primary completion: phase 1 study in Advanced Solid TumorsNCT06384352

TargetBeta

“cMET ADC”the company's pipeline, read by Claude · source

Other programs on MET

ProgramCompanyFurthest phaseStudies
cabozantinibruleExelixisphase 436
CrizotinibrulePfizerphase 431
telisotuzumab adizutecanAbbViephase 318
zanzalintinibruleExelixisphase 317
amivantamabruleJohnson & Johnsonphase 316
vebreltinibrulebeijing-pearl-biotechnology-limited-liability-companyphase 39
glumetinibruleHaihe Biopharmaphase 38
vilzemetkibSino Biopharmaceuticalphase 38
dalmelitinibHansoh Pharmaceutical Groupphase 37
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
SHR-1826Jiangsu HengRui Medicinephase 27

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06384352Advanced Solid Tumors · United States, Australia, Canada and more1RecruitingJun 30, 2031500

How it is read

Names in the registry

  • “YL211”, 1 entry
  • “YL211+Pembrolizumab”, 1 entry
  • “YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)”, 1 entry

Codes read as this program: YL211.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.